| Bioactivity | BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment[1]. |
| Target | IC50: Bruton kinase (BTK) |
| In Vivo | BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33[1]. Animal Model: |
| Name | BTK inhibitor 10 |
| CAS | 2241732-30-7 |
| Formula | C25H23N5O3 |
| Molar Mass | 441.48 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525 |
BTK inhibitor 10
CAS: 2241732-30-7 F: C25H23N5O3 W: 441.48
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, exampl
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.